Quarterly Report January - March 2003

QUARTERLY REPORT JANUARY - MARCH 2003 · Sales increased by 24 percent to SEK 141.3 (113.7) million. Adjusted for changes in exchange rates, sales increased by 33 percent. · On a rolling 12 months basis sales rose by 29 percent to SEK 545.4 (422.5) million. · Q-Med divested the North American business concerning the esthetics products RESTYLANE®, RESTYLANE® Fine Lines and PERLANE(TM) to Medicis (NYSE: MRX) for USD 160 million. A first payment of USD 58.2 million, corresponding to SEK 487.2 million, was received on March 10. A net revenue of SEK 473.6 million is recorded after the deduction of acquisition costs. · Operating income, adjusted for the above-mentioned revenue, amounted to SEK 4.7 (12.9) million. For Q-Med's largest business unit, Estethics, operating income increased by 58 percent to SEK 44.8 millon. · Income after financial items amounted to SEK 476.3 (12.9) million and the cash flow to SEK 465.0 (-34.4) million. · Earnings per share amounted to SEK 19.20 (0.44). Queries should be addressed to Bengt Ågerup, President and CEO, on 018-474 90 00 or 0+46 70-974 90 25, or to Fredrik Hallstan, Director of Investor Relations and Corporate Communications, on +46 70-974 90 15. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/05/12/20030512BIT00880/wkr0001.doc The Full Report http://www.waymaker.net/bitonline/2003/05/12/20030512BIT00880/wkr0002.pdf The Full Report